JP2019137703A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019137703A5 JP2019137703A5 JP2019104562A JP2019104562A JP2019137703A5 JP 2019137703 A5 JP2019137703 A5 JP 2019137703A5 JP 2019104562 A JP2019104562 A JP 2019104562A JP 2019104562 A JP2019104562 A JP 2019104562A JP 2019137703 A5 JP2019137703 A5 JP 2019137703A5
- Authority
- JP
- Japan
- Prior art keywords
- tablet
- iron oxide
- titanium dioxide
- light stabilizer
- red
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims 36
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 34
- 239000004408 titanium dioxide Substances 0.000 claims 17
- 239000004611 light stabiliser Substances 0.000 claims 13
- CEZCCHQBSQPRMU-LLIZZRELSA-L Allura red AC Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1\N=N\C1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-LLIZZRELSA-L 0.000 claims 9
- 239000004191 allura red AC Substances 0.000 claims 9
- 235000012741 allura red AC Nutrition 0.000 claims 9
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 7
- 229910052782 aluminium Inorganic materials 0.000 claims 7
- 239000011248 coating agent Substances 0.000 claims 7
- 238000000576 coating method Methods 0.000 claims 7
- YOZBGTLTNGAVFU-UHFFFAOYSA-N roxadustat Chemical compound C1=C2C(C)=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C1OC1=CC=CC=C1 YOZBGTLTNGAVFU-UHFFFAOYSA-N 0.000 claims 7
- 239000000654 additive Substances 0.000 claims 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- 230000000996 additive effect Effects 0.000 claims 4
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 3
- 229960001681 croscarmellose sodium Drugs 0.000 claims 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 3
- 229960001021 lactose monohydrate Drugs 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- 229940057948 magnesium stearate Drugs 0.000 claims 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 3
- 229940069328 povidone Drugs 0.000 claims 3
- 208000007502 anemia Diseases 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 235000010980 cellulose Nutrition 0.000 claims 2
- 239000013081 microcrystal Substances 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 239000010936 titanium Substances 0.000 claims 1
- 229910052719 titanium Inorganic materials 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021057424A JP2021100971A (ja) | 2013-06-06 | 2021-03-30 | Ｈｉｆプロリルヒドロキシラーゼ阻害剤の医薬製剤 |
| JP2023049709A JP2023068197A (ja) | 2013-06-06 | 2023-03-27 | Ｈｉｆプロリルヒドロキシラーゼ阻害剤の医薬製剤 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361831909P | 2013-06-06 | 2013-06-06 | |
| US61/831,909 | 2013-06-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016517984A Division JP6604941B2 (ja) | 2013-06-06 | 2014-06-05 | Ｈｉｆプロリルヒドロキシラーゼ阻害剤の医薬製剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021057424A Division JP2021100971A (ja) | 2013-06-06 | 2021-03-30 | Ｈｉｆプロリルヒドロキシラーゼ阻害剤の医薬製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019137703A JP2019137703A (ja) | 2019-08-22 |
| JP2019137703A5 true JP2019137703A5 (https=) | 2019-11-14 |
| JP6861758B2 JP6861758B2 (ja) | 2021-04-21 |
Family
ID=51063834
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016517984A Active JP6604941B2 (ja) | 2013-06-06 | 2014-06-05 | Ｈｉｆプロリルヒドロキシラーゼ阻害剤の医薬製剤 |
| JP2019104562A Active JP6861758B2 (ja) | 2013-06-06 | 2019-06-04 | Ｈｉｆプロリルヒドロキシラーゼ阻害剤の医薬製剤 |
| JP2021057424A Withdrawn JP2021100971A (ja) | 2013-06-06 | 2021-03-30 | Ｈｉｆプロリルヒドロキシラーゼ阻害剤の医薬製剤 |
| JP2023049709A Pending JP2023068197A (ja) | 2013-06-06 | 2023-03-27 | Ｈｉｆプロリルヒドロキシラーゼ阻害剤の医薬製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016517984A Active JP6604941B2 (ja) | 2013-06-06 | 2014-06-05 | Ｈｉｆプロリルヒドロキシラーゼ阻害剤の医薬製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021057424A Withdrawn JP2021100971A (ja) | 2013-06-06 | 2021-03-30 | Ｈｉｆプロリルヒドロキシラーゼ阻害剤の医薬製剤 |
| JP2023049709A Pending JP2023068197A (ja) | 2013-06-06 | 2023-03-27 | Ｈｉｆプロリルヒドロキシラーゼ阻害剤の医薬製剤 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20160120859A1 (https=) |
| EP (2) | EP3003284B1 (https=) |
| JP (4) | JP6604941B2 (https=) |
| KR (3) | KR20220164069A (https=) |
| CN (5) | CN111728951A (https=) |
| AU (1) | AU2014274890B2 (https=) |
| CA (1) | CA2914049C (https=) |
| CY (1) | CY1122951T1 (https=) |
| DK (1) | DK3003284T3 (https=) |
| ES (1) | ES2786924T3 (https=) |
| HR (1) | HRP20200615T1 (https=) |
| HU (1) | HUE049623T2 (https=) |
| IL (3) | IL296484B2 (https=) |
| LT (1) | LT3003284T (https=) |
| ME (1) | ME03777B (https=) |
| MX (3) | MX2015016536A (https=) |
| PL (1) | PL3003284T3 (https=) |
| PT (1) | PT3003284T (https=) |
| RS (1) | RS60464B1 (https=) |
| SG (1) | SG11201509764RA (https=) |
| SI (1) | SI3003284T1 (https=) |
| SM (1) | SMT202000190T1 (https=) |
| WO (1) | WO2014197660A1 (https=) |
| ZA (1) | ZA201508712B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004108681A1 (en) | 2003-06-06 | 2004-12-16 | Fibrogen, Inc. | Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin |
| JP5649584B2 (ja) | 2008-11-14 | 2015-01-07 | フィブロジェン インコーポレイテッド | Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体 |
| AU2013290438C1 (en) | 2012-07-16 | 2019-01-03 | Kyntra Bio, Inc. | Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid |
| EP3219706A1 (en) | 2012-07-16 | 2017-09-20 | Fibrogen, Inc. | Process for making isoquinoline compounds |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| HRP20200615T1 (hr) | 2013-06-06 | 2020-07-10 | Fibrogen, Inc. | Farmaceutske formulacije inhibitora hif hidroksilaze |
| US11324734B2 (en) * | 2015-04-01 | 2022-05-10 | Akebia Therapeutics, Inc. | Compositions and methods for treating anemia |
| WO2019042485A1 (en) | 2017-08-30 | 2019-03-07 | Zentiva, K.S. | FORMS IN THE STRONG STATE OF ROXADUSTAT |
| WO2019042641A1 (en) | 2017-09-04 | 2019-03-07 | Sandoz Ag | CO-CRYSTAL OF A HIF PROLYL HYDROXYLASE INHIBITOR AVAILABLE ORALLY |
| CN110664814A (zh) * | 2019-10-24 | 2020-01-10 | 上海长海医院 | Fg-4592在制备治疗炎性肠病药物中的用途 |
| CN110934833B (zh) * | 2019-12-17 | 2022-08-19 | 河北长天药业有限公司 | 一种复方氨酚那敏颗粒 |
| US20230190731A1 (en) * | 2020-03-17 | 2023-06-22 | Zydus Lifesciences Limited | Formulation comprising hif prolyl hydroxylase inhibitors |
| US20220280482A1 (en) * | 2021-03-06 | 2022-09-08 | Mind Medicine, Inc. | Formulations of psilocin that have enhanced stability |
| CN116832005A (zh) * | 2022-03-23 | 2023-10-03 | 石药集团中奇制药技术（石家庄）有限公司 | 一种罗沙司他胶囊 |
| CN114796280B (zh) * | 2022-06-15 | 2024-06-25 | 河北长天药业有限公司 | 一种复方氨酚那敏颗粒及其制备工艺 |
| EP4321155A1 (en) | 2022-08-08 | 2024-02-14 | Sanovel Ilac Sanayi Ve Ticaret A.S. | An oral pharmaceutical composition comprising roxadustat |
| WO2025111214A1 (en) | 2023-11-22 | 2025-05-30 | Fibrogen, Inc. | [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3- carbonyl)amino]acetic acid (roxadustat) for the treatment of anemia in subjects with myelodysplastic syndrome (mds) |
| CN118436652A (zh) * | 2024-04-18 | 2024-08-06 | 南方医科大学顺德医院(佛山市顺德区第一人民医院) | 一种罗沙司他药物制剂及其应用 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0650961T3 (da) | 1993-11-02 | 1997-09-15 | Hoechst Ag | Substituerede heterocykliske carboxylsyreamider, deres fremstilling og deres anvendelse som lægemidler. |
| DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| US8318703B2 (en) * | 2001-12-06 | 2012-11-27 | Fibrogen, Inc. | Methods for improving kidney function |
| DK2298301T3 (en) | 2001-12-06 | 2018-10-01 | Fibrogen Inc | MEDICINALS FOR TREATMENT OF ANEMIA ASSOCIATED WITH Kidney Disease |
| DE10209692A1 (de) | 2002-03-06 | 2003-09-18 | Merck Patent Gmbh | Isochinolinderivate |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US7618940B2 (en) * | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| JP4805234B2 (ja) * | 2002-12-16 | 2011-11-02 | キッセイ薬品工業株式会社 | 経口固形医薬 |
| JP4633469B2 (ja) | 2002-12-16 | 2011-02-16 | キッセイ薬品工業株式会社 | 経口固形医薬 |
| WO2004108681A1 (en) | 2003-06-06 | 2004-12-16 | Fibrogen, Inc. | Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| EP1658074B1 (en) | 2003-08-01 | 2012-11-07 | Fibrogen, Inc. | Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers |
| CN1929847B (zh) * | 2004-03-16 | 2011-01-19 | 旭化成制药株式会社 | 含有法舒地尔的制剂及改善其稳定性的方法 |
| US8703795B2 (en) | 2005-03-02 | 2014-04-22 | Fibrogen, Inc. | Thienopyridine compounds, and methods of use thereof |
| AU2006254897A1 (en) | 2005-06-06 | 2006-12-14 | Fibrogen, Inc. | Improved treatment for anemia using a HIF-alpha stabilising agent |
| MX2007016160A (es) | 2005-06-15 | 2008-03-07 | Fibrogen Inc | Uso de moduladoers de hif-1 alfa para el tratamiento contra el cancer. |
| UA97349C2 (uk) | 2005-09-08 | 2012-02-10 | Х. Луннбэк А/С | Стійкі тверді склади сертиндолу |
| WO2007052592A1 (ja) | 2005-10-31 | 2007-05-10 | Kowa Co., Ltd. | 光安定性に優れた医薬製剤 |
| GB0523810D0 (en) | 2005-11-23 | 2006-01-04 | Astrazeneca Ab | Pharmaceutical compositions |
| BRPI0707302B8 (pt) | 2006-01-27 | 2021-05-25 | Fibrogen Inc | compostos de cianoisoquinolina que atuam no dano tecidual associado com isquemia, hipóxia e anemia, bem como composição farmacêutica que os compreende |
| CA2635841A1 (en) * | 2006-02-09 | 2007-08-16 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical formulations of montelukast sodium |
| WO2007097929A1 (en) | 2006-02-16 | 2007-08-30 | Fibrogen, Inc. | Compounds and methods for treatment of stroke |
| BRPI0710527B8 (pt) | 2006-04-04 | 2021-05-25 | Fibrogen Inc | compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende |
| WO2007141743A2 (en) * | 2006-06-06 | 2007-12-13 | Ranbaxy Laboratories Limited | A tablet dosage form comprising cetirizine and pseudoephedrine |
| US20070293575A1 (en) | 2006-06-15 | 2007-12-20 | Fibrogen, Inc. | Compounds and methods for treatment of cancer-related anemia |
| US7713986B2 (en) | 2006-06-15 | 2010-05-11 | Fibrogen, Inc. | Compounds and methods for treatment of chemotherapy-induced anemia |
| JP5683058B2 (ja) * | 2007-04-27 | 2015-03-11 | ニプロ株式会社 | 経口固形製剤及びその製造方法 |
| TW200924768A (en) * | 2007-10-12 | 2009-06-16 | Astrazeneca Ab | Composition |
| WO2009058403A1 (en) | 2007-11-02 | 2009-05-07 | Fibrogen, Inc. | Methods for reducing blood pressure |
| WO2009073669A1 (en) | 2007-12-03 | 2009-06-11 | Fibrogen, Inc. | Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions |
| EP2231157A1 (en) | 2007-12-06 | 2010-09-29 | Fibrogen, Inc. | Methods for increasing endothelial progentior cells |
| WO2009075826A1 (en) | 2007-12-07 | 2009-06-18 | Fibrogen, Inc. | Methods for increasing white blood cells |
| EP2252619B1 (en) | 2008-01-11 | 2013-10-09 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
| WO2009100250A1 (en) | 2008-02-05 | 2009-08-13 | Fibrogen, Inc. | Chromene derivatives and use thereof as hif hydroxylase activity inhibitors |
| US8217043B2 (en) | 2008-08-20 | 2012-07-10 | Fibrogen, Inc. | Compounds and methods for their use |
| WO2010024908A1 (en) | 2008-08-26 | 2010-03-04 | Fibrogen, Inc. | Methods for treatment of multiple sclerosis |
| JP5649584B2 (ja) | 2008-11-14 | 2015-01-07 | フィブロジェン インコーポレイテッド | Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体 |
| US20100144737A1 (en) | 2008-12-08 | 2010-06-10 | Fibrogen, Inc. | Methods for inhibiting t helper cell differentiation |
| KR20110117133A (ko) | 2009-01-29 | 2011-10-26 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 내핵을 갖는 구강 내 붕괴 정 |
| JP2010248106A (ja) * | 2009-04-14 | 2010-11-04 | Dainippon Sumitomo Pharma Co Ltd | フィルムコーティング錠 |
| JP2012176899A (ja) * | 2009-05-19 | 2012-09-13 | Mitsubishi Tanabe Pharma Corp | ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液 |
| US20140057941A1 (en) | 2011-01-13 | 2014-02-27 | Kin-Hung (Peony) Yu | Methods For Increasing Mean Corpuscular Volume |
| US20140171465A1 (en) * | 2011-01-13 | 2014-06-19 | Fibrogen, Inc. | Methods For Increasing Reticulocyte Hemoglobin Content |
| WO2012106472A1 (en) | 2011-02-02 | 2012-08-09 | Fibrogen, Inc. | Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase |
| CN104024227B8 (zh) | 2011-07-22 | 2025-07-29 | 北京贝美拓新药研发有限公司 | 抑制脯氨酸羟化酶活性的化合物的晶型及其应用 |
| WO2013070908A1 (en) | 2011-11-09 | 2013-05-16 | Fibrogen, Inc. | Therapeutic method |
| WO2013134660A1 (en) | 2012-03-09 | 2013-09-12 | Fibrogen, Inc. | 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors |
| EP3219706A1 (en) | 2012-07-16 | 2017-09-20 | Fibrogen, Inc. | Process for making isoquinoline compounds |
| AU2013290438C1 (en) | 2012-07-16 | 2019-01-03 | Kyntra Bio, Inc. | Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| AU2014209319B2 (en) | 2013-01-24 | 2018-04-19 | Fibrogen, Inc. | Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid |
| HRP20200615T1 (hr) | 2013-06-06 | 2020-07-10 | Fibrogen, Inc. | Farmaceutske formulacije inhibitora hif hidroksilaze |
-
2014
- 2014-06-05 HR HRP20200615TT patent/HRP20200615T1/hr unknown
- 2014-06-05 HU HUE14735770A patent/HUE049623T2/hu unknown
- 2014-06-05 KR KR1020227041268A patent/KR20220164069A/ko not_active Ceased
- 2014-06-05 CA CA2914049A patent/CA2914049C/en active Active
- 2014-06-05 EP EP14735770.1A patent/EP3003284B1/en not_active Revoked
- 2014-06-05 SG SG11201509764RA patent/SG11201509764RA/en unknown
- 2014-06-05 ME MEP-2020-79A patent/ME03777B/me unknown
- 2014-06-05 JP JP2016517984A patent/JP6604941B2/ja active Active
- 2014-06-05 IL IL296484A patent/IL296484B2/en unknown
- 2014-06-05 RS RS20200417A patent/RS60464B1/sr unknown
- 2014-06-05 CN CN202010591483.2A patent/CN111728951A/zh active Pending
- 2014-06-05 PL PL14735770T patent/PL3003284T3/pl unknown
- 2014-06-05 ES ES14735770T patent/ES2786924T3/es active Active
- 2014-06-05 AU AU2014274890A patent/AU2014274890B2/en active Active
- 2014-06-05 SM SM20200190T patent/SMT202000190T1/it unknown
- 2014-06-05 WO PCT/US2014/041021 patent/WO2014197660A1/en not_active Ceased
- 2014-06-05 US US14/896,353 patent/US20160120859A1/en not_active Abandoned
- 2014-06-05 MX MX2015016536A patent/MX2015016536A/es active IP Right Grant
- 2014-06-05 DK DK14735770.1T patent/DK3003284T3/da active
- 2014-06-05 KR KR1020157034392A patent/KR102291860B1/ko active Active
- 2014-06-05 CN CN201480031209.2A patent/CN105377242A/zh active Pending
- 2014-06-05 KR KR1020217025795A patent/KR20210104173A/ko not_active Ceased
- 2014-06-05 CN CN202010591484.7A patent/CN111728952A/zh active Pending
- 2014-06-05 CN CN202010591474.3A patent/CN111728950A/zh active Pending
- 2014-06-05 CN CN201910744577.6A patent/CN110448537A/zh active Pending
- 2014-06-05 PT PT147357701T patent/PT3003284T/pt unknown
- 2014-06-05 IL IL298998A patent/IL298998B2/en unknown
- 2014-06-05 EP EP20156653.6A patent/EP3708154A1/en not_active Withdrawn
- 2014-06-05 LT LTEP14735770.1T patent/LT3003284T/lt unknown
- 2014-06-05 SI SI201431529T patent/SI3003284T1/sl unknown
-
2015
- 2015-11-24 IL IL242759A patent/IL242759B2/en unknown
- 2015-11-26 ZA ZA2015/08712A patent/ZA201508712B/en unknown
- 2015-12-01 MX MX2020003096A patent/MX2020003096A/es unknown
- 2015-12-01 MX MX2022011225A patent/MX2022011225A/es unknown
-
2018
- 2018-07-13 US US16/035,503 patent/US10765672B2/en active Active
-
2019
- 2019-06-04 JP JP2019104562A patent/JP6861758B2/ja active Active
-
2020
- 2020-04-27 CY CY20201100383T patent/CY1122951T1/el unknown
-
2021
- 2021-03-10 US US17/198,013 patent/US20220054474A1/en not_active Abandoned
- 2021-03-30 JP JP2021057424A patent/JP2021100971A/ja not_active Withdrawn
-
2023
- 2023-03-27 JP JP2023049709A patent/JP2023068197A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019137703A5 (https=) | ||
| JP2023123773A5 (https=) | ||
| JP2016523846A5 (https=) | ||
| IL298998B2 (en) | Pharmaceutical formulations of a hif hydroxylase inhibitor | |
| CN1193757C (zh) | 雷诺嗪持续释放制剂 | |
| JP2019059760A5 (https=) | ||
| WO2021231792A1 (en) | Pharmaceutical formulations and uses thereof | |
| JP2021535908A5 (https=) | ||
| JP2018529742A5 (https=) | ||
| JP2015510916A5 (https=) | ||
| JPH07506354A (ja) | 抗虚血薬剤 | |
| JP2006514100A5 (https=) | ||
| RU2011152105A (ru) | Составы таблеток 3-цианохинолина и их применение | |
| US11517571B2 (en) | Use of kinase inhibitors to manage tuberculosis and other infectious diseases | |
| WO2018193648A1 (ja) | アルカリ性化剤による血液浄化 | |
| CN104582684A (zh) | 包含5-氯-n-({(5s)-2-氧代-3-[4-(3-氧代-4-吗啉基)苯基]-1,3-噁唑烷-5-基}甲基)-2-噻吩甲酰胺的药物剂型 | |
| JP2019511465A5 (https=) | ||
| WO2015019237A1 (en) | Pharmaceutical composition of vilazodone | |
| JP2020530447A5 (https=) | ||
| JP7190891B2 (ja) | ダサチニブを有効成分とする医薬錠剤及びその製造方法 | |
| KR101806262B1 (ko) | 수분에 안정한 알긴산 및 카르복시메칠셀룰로오스 소디움 함유 필름코팅정제 | |
| JP2023531930A5 (https=) | ||
| JP7407364B2 (ja) | ラメルテオン含有固形製剤 | |
| WO2025006726A3 (en) | Tmem175 agonists, compositions, and methods of use | |
| RU2014145827A (ru) | Композиция, включающая амлодипин и лозартан, имеющая улучшенную стабильность |